Back Hepatitis B

Hepatitis B

Hepatitis B Patients with HBeAg Seroconversion on Treatment May Not Have Durable Response

People with chronic hepatitis B virus (HBV) who achieve hepatitis B "e" antigen (HBeAg) seroconversion when treated with nucleoside/nucleotide analogs are more likely to experience HBeAg seroreversion and HBV reactivation than those with natural clearance, according to a study described in the November 15, 2012, Journal of Infectious Diseases.alt

Read more:

Entecavir (Baraclude) Label Adds Data on Black Patients and Liver Transplant Recipients with HBV

The U.S. Food and Drug Administration this week approved revised product information for entecavir (Baraclude) for the treatment of chronic hepatitis B virus (HBV) infection, adding new data from studies of African-American patients -- showing no differences in pharmacokinetics or safety -- and of people who received liver transplants. alt

Read more:

Tenofovir Is Safe and Effective for Treating Hepatitis B in Adolescents

Teenagers with chronic hepatitis B virus (HBV) infection responded well to 2 years of treatment with tenofovir (Viread) in the first study of the drug in this population, researchers reported in the August 27, 2012, advance online edition of Hepatology.

alt

Read more:

Entecavir Alone Works as Well as Combo for First-time Hepatitis B Treatment

Treating chronic hepatitis B with entecavir (Baraclude) alone worked as well as dual therapy using entecavir plus tenofovir (Viread) for patients starting treatment for the first time, according to a study described in the September 2012 issue of Gastroenterology. alt

Read more:

ICAAC 2012: Switching to Tenofovir in ART Regimen Suppresses Hepatitis B in HIV/HBV Coinfected

HIV/HBV coinfected people who substituted tenofovir DF (Viread) for zidovudine (AZT; Retrovir) or abacavir (Ziagen) in their antiretroviral regimen saw a reduction in hepatitis B viral load, despite HBV resistance to lamivudine (3TC; Epivir), according to a poster presentation at the 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) this week in San Francisco.

Read more:

Adefovir-resistant Hepatitis B Virus Can Remain Susceptible to Tenofovir

Tenofovir (Viread) continues to be effective for treating chronic hepatitis B patients who have developed resistance to the related drug adefovir (Hepsera), according to a report in the August 14, 2012, online edition of Antiviral Therapy.alt

Read more:

ICAAC 2012: Hepatitis B Vaccine Effective Long-term, but Some Lose Protection after 15 Years

Nearly all children who received 3 doses of the Engerix-B hepatitis B vaccine achieved protective immunity, but about 20% fell below the protective antibody threshold by year 15 and could benefit from a booster shot, Canadian researchers reported at the 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2012) this week in San Francisco. alt

Read more:

Heavy Alcohol Use Impairs Biochemical Response to Entecavir for Chronic Hepatitis B

While obese chronic hepatitis B patients and heavy drinkers did not have impaired virological response to entecavir (Baraclude), alcohol use did reduce the likelihood of alanine aminotransferase (ALT) normalization, according to study findings reported in the June 2012 issue of Clinical and Molecular Hepatology. alt

Read more:

Hepatitis B Rates Higher than Expected among Gay Men, Drug Users, Vaccinated Babies

altAn unexpectedly high proportion of gay/bisexual men and injection drug users develop chronic hepatitis B rather than clearing the infection, Amsterdam researchers reported in the September 2012 Journal of Hepatology. Other recent studies found that more than one-quarter of children born to mothers with hepatitis B showed evidence of "occult" HBV infection despite vaccination at birth, and that some individuals vaccinated as children may still show evidence of infection as adults.

Read more: